Bovine rotavirus VP8*, N-terminal trypsin cleavage product of VP4, was produced in Escherichia coli. To examine if this antigen could induce neutralizing antibody responses, different species of animals were immunized with the recombinant VP8* protein. The VP8* antigen was found to stimulate a neutralizing immune response in rabbits. When VP8*-immunized mice were exposed to bovine rotavirus strain C486, significantly higher antibody responses were observed than if they were only exposed to C486. To simulate a current vaccination protocol in the field with livestock, mice were exposed to live C486 virus first and then to VP8*. These mice had the elevated immune responses indicating that VP8* could boost immunity in primed mice. The immune response to VP8* was also tested in pregnant cows. The efficacy of VP8* in stimulating milk antibody was compared with a commercial inactivated vaccine. Differences in colostral antibody titres between VP8*-vaccinated and unvaccinated cows were statistically significant (P < 0'05) and equivalent to the commercial vaccine (P = 0.0569). The milk antibody titres on day 10 were comparable between VP8*-and commercial vaccine-vaccinated animals and were significantly higher (P < 0.05) than in unvaccinated controls. Furthermore, rabbit and bovine antibodies induced by VP8* were able to neutralize different P types of bovine rotaviruses to varying degrees, suggesting that serotypespecific and cross-reactive epitope(s) are present on the VP8* protein of rotavirus. Taken together, E. coliexpressed VP8* may be useful as a subunit vaccine candidate for bovine rotavirus.
Introduction
Neonatal calf diarrhoea is one of the most common and economically devastating diseases of the cattle industry (Acres, 1977; Snodgrass et al., 1986) . It has been estimated that approximately 5 % of the calves born in North America die from diarrhoea before they reach 1 month of age. These losses cost the cattle industry $1-7 billion annually (Ratafia, 1987) . Since the discovery of bovine rotavirus in faeces of calves suffering from diarrhoea (Mebus et al., 1969) , rotavirus has been shown to be ubiquitous in most mammalian and avian species (Babiuk et al., 1985; Flewett & Babiuk, 1984) . It is therefore important to develop control measures for the prevention of rotaviral disease.
Although cattle of all ages are susceptible to rotavirus infection (Bridger, 1994) , disease occurs primarily in animals less than 1 month of age (Acres, 1977) . Since calves are infected at birth, it is almost impossible to * Author for correspondence. Fax + 1 306 966 7478. e-mail Yoo@sask.usask.ca actively immunize them prior to exposure to virulent field virus. Therefore the best way to reduce economic losses in calves is to vaccinate dams to increase their colostral antibody levels, which is then passively transferred to the calves (Sail et al., 1983) . It is postulated that colostral antibodies in the intestine can neutralize field virus and prevent disease. Depending on the balance between the dose of virus and antibody, animals can be infected and develop immunity without showing clinical disease. Thus, by the time milk antibody levels decline below a protective level the calves will have developed active immunity.
Rotaviruses are comprised of 11 segments of dsRNA molecules surrounded by a triple-layered capsid. The outermost capsid is comprised of protein VP4 and VP7. VP7, a 37 kDa glycoprotein, induces neutralizing antibodies which specify the glycoprotein G serotype . VP4, an 86 kDa non-glycosylated protein, also elicits neutralizing antibodies which specify P serotypes (Gorziglia et al., 1990) . This protein is involved in various virus functions such as haemagglutination (HA; Kalica et al., 1983) , trypsin-enhanced 0001-3277 © 1995 SGM plaque formation (Clark et al., 1981 ) and virus attachment (Crawford et al., 1994) . VP4 cleavage into VP5* and VP8* enhances viral infectivity (Estes et al., 1981) and assists in viral penetration. In studies using neutralizing monoclonal antibodies and a corresponding set of escape mutants, eight neutralization epitopes were identified on VP4 with five of them located on the VP8* subunit (Mackow et al., 1988) . Monoclonal antibodies to VPS* were reported to neutralize rotavirus in vitro and passively protect mice against rotavirus challenge in vivo (Matsui et al., 1989; Offit et al., 1986) . Recently an Escherichia col#expressed N-terminal portion of rotavirus SAll4fM VP4 has been reported to induce neutralizing antibodies as well as to prime the immune system of mice (Lizano et al., 1991) . These studies all suggest that VP8* plays an important role in viral infectivity, and immunity to this protein may be crucial in providing protection from infection.
In our attempt to determine if bovine rotavirus VP8* could elicit neutralizing immune response, we immunized animals with E. coli-produced recombinant VPS* (rVP8*) and assayed sera for their abilities to neutralize virus infectivity. Although rVP8* may not contain all the conformational epitopes involved in virus neutralization, it not only induced neutralizing antibodies but also primed the immune response of vaccinated animals.
Methods
Cells" and viruses. All rotavirus strains were propagated in MA-104 cell monolayers as reported previously (Babiuk et al., 1977) . After incubating for 24 h at 37 °C, supernatant containing the virus was collected and cell debris was removed by centrifugation at 5820 g for 20 min. For immunization studies, virus present in the supernatant was concentrated by centrifugation at 120000 g for 3 h at 15 °C through a 40% sucrose cushion containing 10 mN-CaC12. The virus pellet was resuspended in 100 gl of double-distilled water and then diluted 1:800 in distilled water. The amount of virus protein was measured spectrophotometrically using the formula: 183(A~30)-75.8(A~0)x 800 = gg/ml.
Construction of bacterial expression plasmid pGH432 VP8. The bovine rotavirus C486 VP8* gene from pTZ19RVP4 previously reported by Potter et al. (1987) was amplified by PCR using two primers: 5' ggatccgcATGGCTTCACTCATTTA 3' (BamHI site shown in lower case) for the forward primer and 5' ccatggtcaTCTTGTATATAC-AATA 3' for the reverse primer (lower case represents NcoI site). The cycles of PCR were repeated 30 times at 94 °C for 30 s, 50 °C for 30 s and 72 °C for 1 min. The PCR product was filled/phosphorylated with the Klenow fragment of DNA polymerase and then ligated into the HincII site of PUC19. The reamplified VP8* gene in E. coil strain DH5a cells was ligated into the BamHI-NcoI site of the pGH432 expression vector, resulting in pGH432VP8.
Preparation and sotubilization of r VP8* protein produced in E. coli. The procedure for producing VP8* in E. coli and solubilizatiou was a modification of that described previously (van Drunen Littel-van den Hurk et al., 1993) . Briefly, DH5e cells containing pGH432VP8 were grown to late-log phase in L broth, followed by addition of IPTG (final concentration 2 mM) to induce VP8* gene expression under the control of the ptac promoter. Six hours after induction, cells were harvested by low-speed centrifugation (5000 g) for 10 rain. Cell pellets from 100 ml cultures were resuspended in 4 ml of 25 % sucrose in 50 mM-Tris-HC1 pH 8-0 and placed on ice. Lysozyme (10 mg/ml) was added and the suspension was incubated on ice for 10 min, followed by the addition of 30 ml of 2 x RIPA:TET buffer (5:4; 2 x RIPA containing 20 mMTris-HCl pH 8.0, 300 mM-NaC1 and 2 % sodium deoxycholate; TET containing 100 mM-Tris-HCl pH 8.0, 50 mM-EDTA and 2 % Triton X-100). The preparation was sonicated three times for 30 s using a large probe (Sonics Materials) at the 50 duty cycle setting at power 2. The preparation was centrifuged at 15000 g for 15 rain to pellet the VP8* inclusion bodies. To solubilize VP8* protein produced in E. coli, the inclusion bodies were resuspended in distilled water and the suspension was adjusted to a final concentration of 8 M-urea. The protein concentration was determined by SDS PAGE against a BSA standard. The solubilized protein was used directly for immunization studies.
Gel electrophoresis and Western irnmunoblot analysis. Samples containing urea-treated VP8* were separated by electrophoresis through 10% polyacrylamide gels and transferred to nitrocellulose membranes. Antigen-bearing membranes were blocked with 3 % horse serum in 10mN-PBS for 1 h. After washing with PBS containing 0-05 % Tween-20 (PBST), membranes were incubated for 1 h with a 1:100 dilution of rabbit antiserum to bovine rotavirus C486. After washing with PBST, membranes were incubated for 1 h with biotinconjugated goat anti-rabbit IgG diluted 1:500 in PBST. Membranes were washed and incubated for another 1 h with avidin-horseradish peroxidase {HRP) conjugate diluted 1:500 in PBST. After washing three times with PBST, bound antibody was visualized by a peroxidase substrate kit DAB (Vector Laboratories).
Immunization
(1) Mice. Seven-to 9-week-old female BALB/c mice were screened on day 0 for neutralizing antibody to bovine rotavirus and group A antigen of rotavirus. Preimmune sera at a dilution of 1 : 25 failed to neutralize C486 and sera at a dilution of l : 50 did not react to singleshelled particles of C486 coated on ELISA plates, suggesting that the mice had not been previously exposed to rotavirus. A group of seven seronegative mice was inoculated with 100 gg of E. coli-expressed rVP8* protein in Freund's complete adjuvant. This group was given two boosts separated by a 3 week interval with an identical formulation in Freund's incomplete adjuvant. Mice were bled on day 50 (10 days after last boost).
For determination of the priming effect of rVP8* to C486 or vice versa, two strategies were used: (i) mice were first immunized with rVP8* and then boosted with C486. To do this, two groups of seven seronegative mice received two doses of 100 lag of either E. coliexpressed rVP8* or control E. coli proteins. Six weeks later, all mice were boosted subcutaneously with 50 pg of purified live C486. Sera were taken at day 50 after primary immunization. (ii) Alternatively, mice were first immunized with C486 and then boosted with rVP8*. This experiment was conducted by orally inoculating mice with 107s p.f.u, of live bovine rotavirus C486. Three weeks later, one group of mice was boosted with 10 ~tg of E. coli-expressed VP8* per mouse and the other group of mice was boosted with E. coli proteins. Ten days post-injection with rVP8*, mice were bled and the sera were subjected to plaque reduction assay.
(ii) Rabbits. Prior to immunization, rabbits were screened for evidence of previous exposure to rotavirus by ELISA and virus neutralization assays. Preimmune sera did not neutralize bovine rotavirus C486 at a titre of 1 : 50 nor react to single-shelled particles of C486 coated on ELISA plates. Two seronegative rabbits were immunized with 50 gg of rVP8* protein emulsified with an equal volume of Freund's complete adjuvant on day 0. Three weeks later, rabbits were boosted with rVP8* emulsified in an equal volume of Freund's incomplete adjuvant. Ten days after boosting, rabbits were bled for determination of antibody responses.
(iii) Cattle, One hundred and twenty pregnant cows were randomized into three groups of 40 each. Approximately 7 weeks prior to the onset of calving, all groups were vaccinated with Ecolan (a commercial E. coli vaccine). Concurrently, one group was vaccinated with PBS in a proprietary adjuvant, VSA (Biostar), another group with 50 lag of E.
coli-expressed rVP8* in VSA, and a third group with a rotavirus commercial vaccine (ScourGuard; SmithKline Beecham). Four weeks before calving, each group was revaccinated with the same formulation. Colostrum and milk samples were collected at 12 h and 10 days after calving.
ELISA. A modification of the indirect ELISA procedure was used for the quantification of rotavirus antibodies (van Drunen Littel-van den Hurk et al., 1993) . Briefly, each well of the plate (Immulon 2; Dynatech Laboratories) was coated overnight with different concentrations of 0.5 lag of purified C486 diluted in 0-05 M-carbonate bicarbonate buffer pH 9.6. Unabsorbed virus was removed by extensive washing with distilled water. The plate was incubated with 3 % normal horse serum (Vectastain; Vector Laboratories) to reduce non-specific binding. Serial twofold dilutions of rabbit sera were added to the plate. After 1 h of incubation at room temperature, the plate was washed with PBST before the addition of biotinylated anti-rabbit IgG conjugate, diluted 1 : 1000 in PBST. After incubating at room temperature for 1 h, the plate was washed with PBST before the addition of 1 : 1000 diluted avidin-HRP conjugate. After 1 h, 0.1 N-citric acid containing 1 mg/ml of ABTS [2,2'-amino-di-(3-ethylbenzthiazoline sulphonate)] and 0"015% H~O 2 was added. The reaction was stopped after 10 min by the addition of 10% SDS. The absorbance was read on an ELISA reader at 405 nm.
To analyse epitope integrity, a neutralizing monoclonal antibodybased ELISA was used (Crawford et al., 1994) . Briefly, each well of the ELISA plate (Immulon 2) was coated with 10 lag of monoclonal antibody ascites (2E8) diluted in carbonate bicarbonate buffer. The plate was incubated overnight at room temperature and then washed four times with distilled water. The plate was blocked with 3 % normal horse serum in 10 mM-PBS for 1 h at room temperature. Urea-treated rVP8* or sucrose-purified bovine rotavirus C486 were diluted twofold in PBST containing 1% normal horse serum. The reactions were incubated for 1 h at room temperature. After washing four times with PBST, 100 lal of a 1 : 100 dilution of rabbit antisera to bovine rotavirus C486 was added. The reaction was developed using a biotinylated secondary antibody and avidin-HRP as described above.
Virus neutralization assays.
A plaque assay for the quantification of neutralizing antibody in mouse, rabbit and cattle sera and colostra was performed by the method described previously (Aha & Sabara, 1990) . For independent studies of cross-reactivity between bovine rotavirus serotypes, serum neutralization tests of rabbit sera and randomly selected colostra were performed at the University of Montreal by a modification of the procedure of Brtissow et al. (1991) using the fluorescent focus reduction test.
HA and HA inhibition (H D tests.
HA assays were performed in round-bottom 96-well microplates. Immunogens were diluted twofold in 10 mM-PBS. An equal volume of 0-5 % guinea-pig erythrocytes in PBS containing 0.2 % BSA was added to each well. For the HI test, antisera or ascites were treated with an equal volume of 10% kaolin in PBS. The sera were serially diluted in PBS and then mixed with an equal volume (50 lal) of 8 HA units of C486 or rVP8*. After incubation for 1 h at room temperature, 50 lal of 0"5 % guinea-pig erythrocytes were added and the inhibition of HA was scored after incubation at room temperature for 2 h.
Statistical aria@sis. Statistical analysis of differences in antibody titres was done by the two independent sample t-test. Fig. 1 (a) a n d (b) , lanes 2 a n d 4, r e s p e c t i v e l y , clearly i n d i c a t e the p r e s e n c e o f V P 8 * . T o d e t e r m i n e w h e t h e r or n o t u r e a d e s t r o y e d the c o nf o r m a t i o n a l i n t e g r i t y o f E. col#expressed V P 8 * , H A a n d H I a s s a y s w e r e p e r f o r m e d u s i n g t h e u r e a -t r e a t e d r V P 8 * .
Results

Expression and enrichment o f rVPS
A s s h o w n in T a b l e 1, u r e a -t r e a t e d r V P 8 * h a e m a gg l u t i n a t e d g u i n e a -p i g e r y t h r o c y t e s a n d its H A a c t i v i t y containing pGH432VP8 were grown to late-log phase and the protein expression was induced by IPTG. Total cell lysates were subjected to 10% SDS PAGE and then stained with Coomassie blue (a). Alternatively, the resolved proteins were transferred to nitrocellulose and reacted with rabbit antisera to bovine rotavirus. Bound antibodies were visualized using a biotinylated secondary antibody and avidin HRP conjugate as described in Methods (b was inhibited by a neutralizing monoclonal antibody (2E8) and polyclonal antibodies, indicating conformational integrity. The urea-treated rVP8* was also detected using a monoclonal antibody-based ELISA for reactivity with 2E8, specific to VP8* of bovine rotavirus C486.
Immune response to E. col#expressed VP8* protein (i) Immune response in mice
To test the capability of E. coli-expressed VP8* protein to elicit an immune response, rVP8* was injected into one group of mice and control bacterial antigen injected into a control group. Mice immunized with rVP8* developed neutralizing and HA-inhibiting antibodies with mean titres of 192 and 60, respectively (Fig. 2) , indicating that rVP8* was not only immunogenic but induced antibody that could inhibit the biological function of rotavirus. Mice immunized twice with rVP8* first and then boosted with whole virus (C486) developed significantly higher neutralizing and HA-inhibiting antibody titres than mice immunized with rVP8* alone (Fig.  2) , suggesting that rVP8* primed mice to respond to whole virus. Under the normal field situation, cattle are often exposed to field strains of rotavirus and then vaccinated. To determine whether vaccination with rVP8* could increase the immune response to rotavirus under the simulated field condition (i.e. previous exposure to virus), mice were first orally exposed to bovine rotavirus C486 and then boosted with rVP8*. On day 30 (10 days after boosting), the boosted group had higher neutralizing antibody, with a titre of 160, than the nonboosted animals (titres 1:60).
(
ii) Immune responses in rabbits and cattle
To confirm neutralizing immune responses of other animal species to E. coli-expressed VP8* protein, rabbits were immunized twice with rVP8*, with a 3 week interval, and bled 10 days after the second immunization. Virus-neutralizing antibody titres of 1250 and ELISA titres of 6250 were detected in the rVP8*-immunized rabbits, while control animals retained no increase in neutralizing ( < 1 : 50) and ELISA (< 1 : 100) titres. This result encouraged us to carry out a clinical trial in cattle. One hundred and twenty pregnant cows were randomized into three groups of 40 each. All groups were vaccinated with Ecolan (a commercial vaccine to prevent diarrhoea caused by enterotoxigenic E. coli). One group served as a control and was vaccinated with adjuvant alone, another group was immunized with E. col#expressed VP8*, and a third group was vaccinated with a commercial inactivated rotavirus/coronavirus vaccine (ScourGuard). In order to assess the degree of natural immunity, all cows were bled at the time of immunization. All groups had a mean neutralizing antibody titre of 1000-2700. These results indicated that all animals had previously been exposed to rotavirus, as expected. Three weeks later, all cows were revaccinated with the respective vaccines. At 12 h and 10 days after calving, colostra and milk were collected to assay for the presence of neutralizing antibodies. Geometric mean neutralizing antibody titres (Fig. 3 a) to bovine rotavirus C486 in colostra from vaccinated cows were 17000 and 17 154 in ScourGuard-and rVP8*-immunized animals, respectively. Colostra from control cows had a titre of 9461. Although the differences in colostral antibody titres between the group of animals immunized with the commercial vaccine and rVP8-vaccinated cows was not quite significant (P = 0.0569), titres from those animals immunized with the E. coli-expressed VP8* protein were significantly different from the controls (P = 0.0421). The colostral neutralizing antibody titre induced by the rVP8* and commercial vaccines rapidly decreased so that by 10 days post-calving, neutralizing milk antibody titres were 510 and 466, respectively (Fig. 3b) . The control group neutralizing titre also decreased to 221. The difference in antibody titres between vaccinated One hundred and twenty pregnant cows were randomized into three groups of 40 each. After two immunizations separated by a 3 week interval, colostrum and milk were collected 12 hours and 10 days after calving, respectively. Rotavirus-neutralizing antibody titres (mean _+sEr~) were measured by the virus neutralization test of Aha & Sabara (1990) and are expressed as the highest dilution of the colostrum and milk: control (I-q); commercial vaccine ([~); rVPS* (1). VN, virus neutralization. * Neutralizing antibodies were tested for their ability to neutralize the indicated viruses. The test was performed by a modification of the procedure of Brfissow et al. (1991) . Titres are expressed as the reciprocal of the highest dilution of the serum or colostrum that neutralized at least 50% of foci in the immunofluorescent focus reduction test.
~ Amino acid similarities in a variable region of the VP8* (amino acids 71-204; Hardy et aL, 1992) .
:~ Colostrum from five animals was randomly selected from those carrying the highest neutralizing antibody titres.
(rVP8*-and commercial vaccine-immunized) and control cows was statistically significant (P < 0"05) at day 10 post-calving.
Cross-reactivity of antisera to E. coli-expressed VP8* with different P serotypes
Since cattle are expected to be infected with more than one P serotype, we tested the ability of the antibody induced by rVP8* to neutralize the three known bovine rotavirus P types. For cross-reactivity study, we used five cattle sera carrying the highest neutralizing antibody titres. The antibody titres of selected sera were 81000, while the average titre within the group was about 17 000 (Fig. 3) , suggesting that major antibody titres of selected animals had been generated against rVP8*. Since rotavirus B641 shares the G6 serotype but not the P type with C486, the antibody titre of 14580 that neutralized strain B641 was probably due to the heterotypic neutralization activity of the rVP8*. This is consistent with the data of heterotypic antibody titres using rabbit antisera, since rVP8*-immunized rabbits are all rotavirusnaive (Table 2) . Table 2 indicates that P1 was recognized most strongly, as would be expected since the rVP8* used was cloned from a P1 serotype. P5 was neutralized at an intermediate level and P11 was weakly neutralized.
Discussion
It has been reported that 10 M-urea does not destroy the cell binding and HA activities of reovirus al protein (Yeung et al., 1987) . These authors also reported that urea-treated al protein could induce neutralizing antibodies in animals. This report suggested that 8 M-urea may provide an excellent way to solubilize aggregated proteins since it may not affect the native conformation of functional proteins. As shown in Table 1 , binding of monoclonal antibody 2E8 to urea-treated rVP8* suggested that an epitope involved in binding to neutralizing antibodies was maintained. Furthermore, the rVP8* could bind to erythrocytes and agglutinate them. These results indicate that at least some functional epitope on rVP8* is intact following urea treatment.
It has been reported that some proteins or synthetic peptides of viral origin can prime the immune system of animals, as indicated by enhanced antibody or cellmediated immune responses following exposure to the virus from which the peptides were derived (Arias et al., 1989; Earl et al., 1986; Ijaz et aL, 1991) as well as from a heterologous virus (Emini et al., 1985) . In the latter case, it is especially interesting to see that poliovirusspecific peptides could prime the immune system of rabbits to hepatitis A virus. Since peptides from supposedly unrelated viruses could prime the immune response, it is not surprising that a protein (VP8*) could dramatically increase the neutralizing and HI (functional) antibody response following exposure to wildtype virus (Fig. 2) .
Rotaviral disease is pandemic in cattle and antibodies are detectable in the blood and colostrum of most cows (Babiuk et al., 1985; Snodgrass et aL, 1990; Woode, 1978) . Colostral antibodies protect the offspring against rotaviral diarrhoea for the first several days of life by bathing the intestinal lumen. These antibodies present in the intestinal tract of the calf are much more effective than those found in the circulation . Since milk antibodies decline rapidly in cattle, the calf often becomes naturally infected with rotavirus as maternal milk antibody titres decline (Acres & Babiuk, 1978) . It has been postulated that calves can develop active intestinal (mucosal) immunity in the presence of passive antibody (Besser et al., 1988; Mebus et al., 1973) . Thus, by the time all the milk antibody has decayed, there has been sufficient time for active mucosal immunity to develop. Therefore, considerable efforts are under way in order to develop vaccines which will prolong the duration of protective antibody levels in milk, thereby preventing early infection and allowing time for development of active immunity (Babiuk et al., 1985) . In one study, diarrhoea did not develop in calves experimentally infected with rotavirus if the colostrum had a neutralizing antibody titre of 320 (Bridger & Woode, 1975) . Another study indicated that 7-day-old colostrum with a neutralizing titre of 640 only delayed the onset of disease as well as the extent of virus shedding (Snodgrass et al., 1980) . The explanation for these discrepancies was that the quantity of challenge virus can overcome the protective capacity of the antibody (Snodgrass et al., 1980) . These studies all indicate that antibody in the milk is protective but as with any viral infection, immunity can be overcome with a massive challenge. In the present study, maternal antibody titres to E. col#expressed VP8* protein were found to be maintained above 510 for 10 days after birth. Taken together, this indicates that calves born to cows immunized with E. col#expressed VPS* protein may be protected under normal management conditions against natural infection of bovine rotavirus for at least the first 10 days after birth. This would be sufficient time for the animal to begin mounting an active immune response to infection.
The initial bovine rotavirus isolated from cattle (Mebus et al., 1969) was serotype G6 and subsequently a G10 serotype has been reported in cattle (Snodgrass et al., 1990) . Recently, serotype G6 has been reported to contain at least two P serotypes (P1 and P5) and G10 at least one P serotype (Pll) (Parwani et al., 1993) . Although little is known regarding the global distribution and frequency of bovine rotavirus P types, one study reported that G6P5 serotypes were detected most frequently among the bovine rotavirus strains in the USA (Parwani et al., 1993) . These studies suggest that a G6P5 strain may be a better vaccine candidate than a G6P1 strain, presently used as a vaccine in North America. It has been reported that neutralizing antibodies to VP8* cross-react among different serotypes (Larralde et al., 1991) to various degrees. Woode et al. (1983) reported that although antisera of cattle vaccinated with strain NCDV (G6P1) could cross-react with B641 (G6P5) they failed to cross-protect. One of the reasons for the lack of cross-protection between G6P5 and G6P1 may be due to the difference in P types. This view is supported by the analysis of the variable region of VP8* which demonstrated an amino acid similarity of 53% between B641 and NCDV (Hardy et al., 1991) . Since the immunogen used in this study was produced from the VPS* gene encoded by serotype P1, it was of interest to determine whether E. col#expressed VP8* protein could elicit neutralizing antibodies that crossreacted with other serotypes, especially P5 which is widespread in the cattle population (Parwani et al., 1993) . It is encouraging that neutralizing antibodies elicited by rVP8* did cross-react to a considerable level with bovine rotavirus serotype P5 (Table 2 ). However, this reactivity was much lower with a P11 serotype. Since the amino acid similarity between P1 and P11 is only 44% (Table 2 ), the lower cross-reactivity is not surprising.
In summary, the results of the present study demonstrate that E. coli-expressed VP8* protein elicited neutralizing antibodies in seronegative mice and rabbits and significantly increased antibody responses in colostrum and milk of cows (P < 0.05) under normal condition (i.e. previously exposed to rotavirus). Ten days after calving, the rotavirus-neutralizing antibody titres to the vaccine P type in the milk of vaccinated cows remained above the threshold which is considered to be protective for calves. The present data strongly indicate that E. col#expressed VP8* protein may be useful as a subunit vaccine for prevention of serotype P1 rotavirus infection and that other P types will need to be incorporated into the vaccine to provide broad spectrum protection.
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